Anthera Pharmaceuticals Inc., of Hayward, Calif., completed patient recruitment for its phase III RESULT trial testing Sollpura in patients with exocrine pancreatic insufficiency caused by cystic fibrosis. Results of an interim futility analysis are expected in December and top-line data should be available in the first quarter of 2018.